Today the report “Four years of healthy procurement” has been presented (it can be downloaded here). This is the analysis of the four-year experience in the implementation of the international program of drug procurement with focus on oncology, conducted by the Center for Combatting Corruption with the support of the International Renaissance Foundation.
Among the findings of the study are the following:
- Considering only one field, adult oncology, prices for 90% of drugs are now lower than in 2014.
- Whereas in 2014 in the field of pediatric oncology 99.5% of budget funds allocated for drug procurement were transferred to distributors, with only 0.5% of budget funds going to producers, in 2017, few years after the international procurement program has begun, only 33.5% of drugs were purchased by transferring the budget funds to distributors, while 66.3% of contracts for drug purchases were concluded directly with pharmaceutical producers.
- The nomenclature (list) of drugs procured by the state in the field of pediatric oncology grew from 63 to 103 drugs, while in the field of adult oncology the list of drugs increased from 71 to 101. 84% of the drugs procured by the state are produced in the EU.
- The number of suppliers, which won in the biddings, grew from 8 (pediatric oncology) and 6 (adult oncology), respectively, to 26 in each of those fields, which again shows the increased competition.
- Five countries have already borrowed this experience from Ukraine and introduced the like system of drug procurement through international organizations: Bosnia and Herzegovina, Kazakhstan, Moldova, Turkmenistan and Uzbekistan.
As a result of these efforts, patients now receive more free medicines. On the average, the state now buys 30-40% more drugs for the treatment of cancer in adults and children.
